Radioprotective effects of diltiazem on cytogenetic damage and survival in gamma ray exposed mice.
Diltiazem, a calcium ion channel blocker, already in use in cardiovascular therapeutics, has been observed to protect against bone marrow damage (cytogenetic damage, cell death) and mortality in whole body irradiated mice. The micronuclei fraction in bone marrow cells of whole body irradiated (60Co gamma rays, 2.0 Gy) mice was reduced from 2.24 +/- 0.23% to about 0.74 +/- 0.33% by preirradiation administration (-20 min) of 110 mg/kg body wt. diltiazem (ip). Endogenous colony forming unit counts in spleen of mice administered 110 mg/kg body wt. (-20 min) of diltiazem before 10 Gy whole body irradiation were 6 times more than untreated irradiated controls. Pretreatment with diltiazem accelerated the recovery of radiation induced weight loss also. Diltiazem (110 mg/kg body wt, -20 min) enhanced 30 day survival to about 95% and 85% after lethal whole body absorbed dose of 9 and 10 Gy respectively and also mitigated radiation induced life- span shortening. Post-irradiation (10 Gy) administration of diltiazem (+20 to 30 min) enhanced survival from about 2 to 15% only but was highly significant (P < 0.001). Possible modes of radioprotective action of diltiazem have been discussed.
Goel
H C
HC
Institute of Nuclear Medicine & Allied Sciences, Lucknow Marg, Delhi, India.
Ganguly
S K
SK
Prasad
J
J
Jain
V
V
D000818:Animals; D002317:Cardiovascular Agents / Q000494:pharmacology* / Q000633:toxicity; D004110:Diltiazem / Q000494:pharmacology* / Q000633:toxicity; D005260:Female; D005720:Gamma Rays; D051379:Mice; D015162:Micronucleus Tests; D011837:Radiation-Protective Agents / Q000494:pharmacology*; D014916:Whole-Body Irradiation
D002317:Cardiovascular Agents; D011837:Radiation-Protective Agents; D004110:Diltiazem